cGMP signals modulate cAMP levels in a compartment-specific manner to regulate catecholamine-dependent signaling in cardiac myocytes
- PMID: 21330599
- PMCID: PMC3083836
- DOI: 10.1161/CIRCRESAHA.110.230698
cGMP signals modulate cAMP levels in a compartment-specific manner to regulate catecholamine-dependent signaling in cardiac myocytes
Abstract
Rationale: cAMP and cGMP are intracellular second messengers involved in heart pathophysiology. cGMP can potentially affect cAMP signals via cGMP-regulated phosphodiesterases (PDEs).
Objective: To study the effect of cGMP signals on the local cAMP response to catecholamines in specific subcellular compartments.
Methods and results: We used real-time FRET imaging of living rat ventriculocytes expressing targeted cAMP and cGMP biosensors to detect cyclic nucleotides levels in specific locales. We found that the compartmentalized, but not the global, cAMP response to isoproterenol is profoundly affected by cGMP signals. The effect of cGMP is to increase cAMP levels in the compartment where the protein kinase (PK)A-RI isoforms reside but to decrease cAMP in the compartment where the PKA-RII isoforms reside. These opposing effects are determined by the cGMP-regulated PDEs, namely PDE2 and PDE3, with the local activity of these PDEs being critically important. The cGMP-mediated modulation of cAMP also affects the phosphorylation of PKA targets and myocyte contractility.
Conclusions: cGMP signals exert opposing effects on local cAMP levels via different PDEs the activity of which is exerted in spatially distinct subcellular domains. Inhibition of PDE2 selectively abolishes the negative effects of cGMP on cAMP and may have therapeutic potential.
Figures








Similar articles
-
Therapeutic Implications for PDE2 and cGMP/cAMP Mediated Crosstalk in Cardiovascular Diseases.Int J Mol Sci. 2020 Oct 10;21(20):7462. doi: 10.3390/ijms21207462. Int J Mol Sci. 2020. PMID: 33050419 Free PMC article. Review.
-
Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.J Mol Cell Cardiol. 2015 Nov;88:29-38. doi: 10.1016/j.yjmcc.2015.09.011. Epub 2015 Sep 23. J Mol Cell Cardiol. 2015. PMID: 26388264 Free PMC article.
-
Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway.Circ Res. 2006 Feb 3;98(2):226-34. doi: 10.1161/01.RES.0000200178.34179.93. Epub 2005 Dec 15. Circ Res. 2006. PMID: 16357307
-
cGMP-cAMP interplay in cardiac myocytes: a local affair with far-reaching consequences for heart function.Biochem Soc Trans. 2012 Feb;40(1):11-4. doi: 10.1042/BST20110655. Biochem Soc Trans. 2012. PMID: 22260658
-
Cyclic nucleotide phosphodiesterase-mediated integration of cGMP and cAMP signaling in cells of the cardiovascular system.Front Biosci. 2005 May 1;10:1221-8. doi: 10.2741/1614. Front Biosci. 2005. PMID: 15769620 Review.
Cited by
-
Therapeutic Implications for PDE2 and cGMP/cAMP Mediated Crosstalk in Cardiovascular Diseases.Int J Mol Sci. 2020 Oct 10;21(20):7462. doi: 10.3390/ijms21207462. Int J Mol Sci. 2020. PMID: 33050419 Free PMC article. Review.
-
The NO/cGMP pathway inhibits transient cAMP signals through the activation of PDE2 in striatal neurons.Front Cell Neurosci. 2013 Nov 18;7:211. doi: 10.3389/fncel.2013.00211. eCollection 2013. Front Cell Neurosci. 2013. PMID: 24302895 Free PMC article.
-
CNP regulates cardiac contractility and increases cGMP near both SERCA and TnI: difference from BNP visualized by targeted cGMP biosensors.Cardiovasc Res. 2022 May 6;118(6):1506-1519. doi: 10.1093/cvr/cvab167. Cardiovasc Res. 2022. PMID: 33970224 Free PMC article.
-
Differential regulation of C-type natriuretic peptide-induced cGMP and functional responses by PDE2 and PDE3 in failing myocardium.Naunyn Schmiedebergs Arch Pharmacol. 2014 May;387(5):407-17. doi: 10.1007/s00210-013-0953-1. Epub 2014 Jan 15. Naunyn Schmiedebergs Arch Pharmacol. 2014. PMID: 24424715
-
SERCA Cys674 sulphonylation and inhibition of L-type Ca2+ influx contribute to cardiac dysfunction in endotoxemic mice, independent of cGMP synthesis.Am J Physiol Heart Circ Physiol. 2013 Oct 15;305(8):H1189-200. doi: 10.1152/ajpheart.00392.2012. Epub 2013 Aug 9. Am J Physiol Heart Circ Physiol. 2013. PMID: 23934853 Free PMC article.
References
-
- El-Armouche A, Eschenhagen T. Beta-adrenergic stimulation and myocardial function in the failing heart. Heart Fail Rev. 2009;14:225–241. - PubMed
-
- Shah AM, MacCarthy PA. Paracrine and autocrine effects of nitric oxide on myocardial function. Pharmacol Ther. 2000;86:49–86. - PubMed
-
- Rosenkranz AC, Woods RL, Dusting GJ, Ritchie RH. Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP. Cardiovasc Res. 2003;57:515–522. - PubMed
-
- Felker GM, Pang PS, Adams KF, Cleland JG, Cotter G, Dickstein K, Filippatos GS, Fonarow GC, Greenberg BH, Hernandez AF, Khan S, Komajda M, Konstam MA, Liu PP, Maggioni AP, Massie BM, McMurray JJ, Mehra M, Metra M, O’Connell J, O’Connor CM, Pina IL, Ponikowski P, Sabbah HN, Teerlink JR, Udelson JE, Yancy CW, Zannad F, Gheorghiade M. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. Circ Heart Fail. 2010;3:314–325. - PubMed
-
- Nony P, Boissel JP, Lievre M, Leizorovicz A, Haugh MC, Fareh S, de Breyne B. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis. Eur J Clin Pharmacol. 1994;46:191–196. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources